Activity of anti-cancer protein kinase inhibitors against Leishmania spp.

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 7, 2014, Pages 1888-1891

  Sanderson, Lisa ^a   Yardley, Vanessa ^a   Croft, Simon L ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Drug repurposing; Lapatinib; PP2; Sorafenib; Sunitinib

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; AMPHOTERICIN B LIPID COMPLEX; LAPATINIB; MILTEFOSINE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; ANTIPROTOZOAL AGENT; CARBANILAMIDE DERIVATIVE; INDOLE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE;

AMASTIGOTE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIASIS; LIVER; MAMMAL CELL; MOUSE; NONHUMAN; PARASITE LOAD; PERITONEUM MACROPHAGE; SKIN DISEASE; SPLENOMEGALY; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECTS; DRUG REPOSITIONING; IC50; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIPROTOZOAL AGENTS; DISEASE MODELS, ANIMAL; DRUG REPOSITIONING; INDOLES; INHIBITORY CONCENTRATION 50; LEISHMANIA; LEISHMANIASIS; MICE, INBRED BALB C; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRROLES; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84902461096     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku069     Document Type: Article

References (16)

1. Alvar J, Velez ID, Bern C et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012; 7: e35671.
2. Tiuman TS, Santos AO, Ueda-Nakamura T et al. Recent advances in leishmaniasis treatment. Int J Infect Dis 2011; 15: e525-32.
3. Walker RG, Thomson G, Malone K et al. High throughput screens yield small molecule inhibitors of Leishmania CRK3:CYC6 cyclin-dependent kinase. PLoS Negl Trop Dis 2011; 5: e1033.
4. Cleghorn LA, Woodland A, Collie IT et al. Identification of inhibitors of the Leishmania cdc2-related protein kinase CRK3. ChemMedChem 2011; 6: 2214-24.
5. Kar S, Ukil A, Sharma G et al. MAPK-directed phosphatases preferentially regulate pro-and anti-inflammatory cytokines in experimental visceral leishmaniasis: involvement of distinct protein kinase C isoforms. J Leukoc Biol 2010; 88: 9-20.
6. Janne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 2009; 8: 709-23.
7. Parsons M, Worthey EA, Ward PN et al. Comparative analysis of the kinomes of three pathogenic trypanosomatids: Leishmania major, Trypanosoma brucei and Trypanosoma cruzi. BMC Genomics 2005; 6: 127.
8. Karaman MW, Herrgard S, Treiber DK et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127-32.
9. Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents 2000; 13: 243-8.
10. Bopp SK, Lettieri T. Comparison of four different colorimetric and fluorometric cytotoxicity assays in a zebrafish liver cell line. BMC Pharmacol 2008; 8: 8.
11. Actor P. Protein and vitamin intake and visceral leishmaniasis in the mouse. Exp Parasitol 1960; 10: 1-20.
12. Dalton JE, Maroof A, Owens BM et al. Inhibition of receptor tyrosine kinases restores immunocompetence and improves immune-dependent chemotherapy against experimental leishmaniasis in mice. J Clin Invest 2010; 120: 1204-16.
13. Katiyar S, Kufareva I, Behera R et al. Lapatinib-binding protein kinases in the African trypanosome: identification of cellular targets for kinase-directed chemical scaffolds. PLoS One 2013; 8: e56150.
14. Patel G, Karver CE, Behera R et al. Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinibderived lead compound for trypanosomiasis. J Med Chem 2013; 56: 3820-32.
15. Hanke JH, Gardner JP, Dow RL et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck-and FynT-dependent T cell activation. J Biol Chem 1996; 271: 695-701.
16. Lowell CA. Src-family and Syk kinases in activating and inhibitory pathways in innate immune cells: signaling cross talk. Cold Spring Harb Perspect Biol 2011; 3: a002352.